Skip to main content

Advertisement

Table 1 Characteristics of the whole and propensity score-matched cohorts of patients with locoregionally advanced nasopharyngeal carcinoma

From: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis

Characteristic Whole cohort [cases (%)] Propensity score-matched cohort [cases (%)]
Total Cisplatin group Docetaxel group P value Total Cisplatin group Docetaxel group P value
Total 962 737 225   448 224 224  
Age     0.245     0.124
 ≤ 50 years 663 (68.9) 515 (69.9) 148 (65.8)   311 (69.4) 163 (72.8) 148 (66.1)  
 > 50 years 299 (31.1) 222 (30.1) 77 (34.2)   137 (30.6) 61 (27.2) 76 (33.9)  
Sex     0.428     0.912
 Male 716 (74.4) 544 (73.8) 172 (76.4)   341 (76.1) 170 (75.9) 171 (76.3)  
 Female 246 (25.6) 193 (26.2) 53 (23.6)   107 (23.9) 54 (24.1) 53 (23.7)  
Histological type (WHO)
 I 4 (0.4) 3 (0.3) 1 (0.4) 0.939 2 (0.4) 1 (0.4) 1 (0.4) 1.000
 II–III 958 (99.6) 734 (99.7) 224 (99.6)   446 (99.6) 223 (99.6) 223 (99.6)  
Clinical T stagea     0.337     0.278
 T1–T2 226 (23.5) 171 (23.2) 55 (24.4)   114 (25.4) 59 (26.3) 55 (24.6)  
 T3 591 (61.4) 461 (62.6) 130 (57.8)   268 (59.9) 138 (61.6) 130 (58.0)  
 T4 145 (15.1) 105 (14.2) 40 (17.8)   66 (14.7) 27 (12.1) 39 (17.4)  
Clinical N stagea     0.049     0.959
 N0 91 (9.5) 72 (9.8) 19 (8.4)   40 (8.9) 21 (9.4) 19 (8.5)  
 N1 524 (54.5) 398 (54.0) 126 (56.3)   252 (56.3) 126 (56.3) 126 (56.3)  
 N2 297 (30.8) 221 (30.0) 76 (33.8)   151 (33.7) 75 (33.5) 76 (33.9)  
 N3 50 (5.2) 46 (6.2) 4 (1.8)   5 (1.1) 2 (0.9) 3 (1.3)  
Clinical stagea     0.109     0.189
 II 123 (12.8) 85 (11.5) 38 (16.9)   80 (17.9) 42 (10.2) 38 (17.0)  
 III 645 (67.0) 501 (68.0) 144 (64.0)   298 (66.5) 154 (68.8) 144 (64.3)  
 IV 194 (20.2) 151 (20.5) 43 (19.1)   70 (15.6) 28 (12.5) 42 (18.7)  
Pretreatment EBV DNA     0.258     0.694
 < 4000 copies/mL 633 (65.8) 492 (66.8) 141 (62.7)   286 (63.8) 145 (64.7) 141 (62.9)  
 ≥ 4000 copies/mL 329 (34.2) 245 (33.2) 84 (37.3)   162 (36.2) 79 (35.3) 83 (37.1)  
  1. WHO World Health Organization, EBV Epstein–Barr virus
  2. aThe 7th edition of the AJCC/UICC staging system was used for TNM classification